美国女性致癌性人乳头瘤病毒感染个人风险评分(PRO-HPV)的开发与验证
评分可将女性分为低危(<20%)、平均危(20-30%)和高危(>30%)三组,并在2013-14队列中前瞻性验证,校准良好,区分度中等(c-statistics 0.67-0.68)。
要点
- PRO-HPV25和PRO-HPV30评分基于六项自我报告变量,分别适用于25-59岁和30-59岁女性。
- 评分将HRHPV感染风险分为低危(<20%)、平均危(20-30%)和高危(>30%)三组。
- 评分在2013-14队列中验证校准良好,区分度中等(c-statistics 0.67-0.68)。
核心结论
- PRO-HPV风险评分可识别生殖道HRHPV感染低危、平均危和高危女性群体,可用于低资源环境优先筛查或个体化筛查间隔。
研究设计与样本
- 2017年开展的横断面分析,使用2005-14年美国国家健康与营养调查(NHANES)数据,纳入7337名25-59岁女性和6300名30-59岁女性。
- 预测变量为生殖健康实践、风险行为及人口学变量,结局为21种生殖道HRHPV基因型中任一阳性。
- 2005-12队列作为训练集和测试集开发评分,2013-14队列用于验证最终评分。
主要发现
- 开发了两种含六项自我报告变量的两点评分:PRO-HPV25(25-59岁)和PRO-HPV30(30-59岁)。
- 评分在2013-14队列中前瞻性验证,预测与观察的HRHPV感染率校准良好。
- 评分的区分度中等,c-statistics为0.67-0.68。
关键数值与推荐
- 风险分组阈值:低危<20%,平均危20-30%,高危>30%。
- PRO-HPV25适用于25-59岁女性,PRO-HPV30适用于30-59岁女性。
临床怎么用
- 在低资源环境中可利用PRO-HPV评分对女性进行风险分层,优先安排宫颈癌筛查。
- 可根据评分结果个体化调整宫颈癌筛查间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Determining risk scores for genital high-risk human papillomavirus (HRHPV) infection in women will support more efficient cervical cancer screening strategies. OBJECTIVE: We developed and validated point scores to predict the likelihood of any genital HRHPV infection in women. METHODS: We conducted the cross-sectional analysis in 2017 and used data from the 2005-14 US National Health and Nutrition Examination Survey (7337 women aged 25-59 years; 6300 women aged 30-59 years). Predictors were reproductive health practices, risk behaviors and demographic variables. The outcome was a positive result for any of the 21 genital HRHPV genotypes. The 2005-12 cohorts were used as training and testing sets to develop scores that best classified women into three risk groups: low risk (<20%), average risk (20-30%) and high risk (>30%). The 2013-14 cohort was used to validate the final scores. RESULTS: Two-point scores with six self-reported variables were created to predict any HRHPV risks for the two age groups: the Personal Risk of Oncogenic HPV (PRO-HPV25) for women aged 25-59 years old and PRO-HPV30 for women aged 30-59 years old. The scores were successfully prospectively validated, with good calibration with regards to the predicted and observed rates of HRHPV infection. The scores had fair discrimination (c-statistics: 0.67-0.68). CONCLUSION: The PRO-HPV risk scores can identify groups at low, average and high risk of genital HRHPV infection. This information can be used to prioritize women for cervical cancer screening in low-resource settings or to personalize screening intervals.
引用
- Thai TN, Bui TC, Ebell MH, et al. Developing and validating the Personal Risk of Oncogenic Human Papillomavirus infection score in US Women. Fam Pract. 2019. PMID: 30239658. doi:10.1093/fampra/cmy091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。